Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.
Boddu P, et al. Among authors: kadia tm.
Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.
Blood Adv. 2017.
PMID: 29296774
Free PMC article.